. Author manuscript; available in PMC: 2024 Sep 1.

Published in final edited form as: Lancet Infect Dis. 2023 May 10;23(9):1062–1071. doi: 10.1016/S1473-3099(23)00139-1

Table 3:

Faecal shedding of poliovirus 7, 14, and 28 days after first vaccination by study group in the modified intention-to-treat population

nOPV2 only group		nOPV2 plus bOPV group	bOPV only group	χ² test

Poliovirus type 1
Day 7	2/244 (1%; 0–2)	..	..	NA
Day 14	5/242 (2%; 0–4)	125/245 (51%; 45–57)	141/245 (58%; 51–64)	nOPV2 plus bOPV vs bOPV only: p=0.17
Day 28	3/244 (1%; 0–3)	64/246 (26%; 21–31)	77/246 (31%; 26–37)	nOPV2 plus bOPV vs bOPV only: p=0.23
Poliovirus type 2
Day 7	168/244 (69%; 63–75)	..	..	NA
Day 14	161/242 (67%; 61–72)	87/245 (36%; 30–42)	3/245 (1%; 0–3)	nOPV2 only vs nOPV2 plus bOPV: p<0.0001
Day 28	116/244 (48%; 41–54)	73/246 (30%; 24–35)	2/246 (1%; 0–2)	nOPV2 only vs nOPV2 plus bOPV: p<0.0001
Poliovirus type 3
Day 7	7/244 (3%; 1–5)	..	..	NA
Day 14	8/242 (3%; 1–6)	170/245 (69%; 64–75)	151/245 (62%; 56–68)	nOPV2 plus bOPV vs bOPV only: p=0.087
Day 28	8/244 (3%; 1–6)	136/246 (55%; 49–61)	131/246 (53%; 47–59)	nOPV2 plus bOPV vs bOPV only: p=0.72

Data are n/N (%; 95% CI). p values are reported for comparisons of interest (ie, they include comparisons between study vaccines without a specific type). bOPV=bivalent oral poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2. NA=not applicable.